Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Viatris stock in Canada
Own Viatris shares in just a few minutes.
Viatris Inc is a drug manufacturers-specialty & generic business based in the US. Viatris shares (MYL.US) are listed on the NASDAQ and all prices are listed in US Dollars. Viatris employs 35,000 staff and has a trailing 12-month revenue of around $11.5 billion.
How to buy shares in Viatris
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: MYL in this case.
- Research Viatris shares. The platform should provide the latest information available.
- Buy your Viatris shares. It's that simple.
What's in this guide?
- Can I buy shares in Viatris?
- Viatris shares summary
- Compare share dealing platforms
- Is Viatris stock a buy or sell?
- Can I short Viatris shares?
- Is Viatris suitable for ethical investing?
- Are Viatris shares over-valued?
- Viatris's financials
- How volatile are Viatris shares?
- Does Viatris pay a dividend?
- Have Viatris shares ever split?
- Other common questions
Viatris share priceUse our graph to track the performance of MYL stocks over time.
Viatris shares at a glance
|Latest market close||$N/A|
|52-week range||$0.077 - $19.02|
|50-day moving average||$16.4214|
|200-day moving average||$16.1173|
|Wall St. target price||$21.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.516|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Viatris stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Viatris under- or over-valued?
Valuing Viatris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Viatris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Viatris's P/E ratio
Viatris's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Viatris shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Viatris's PEG ratio
Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Viatris's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Viatris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.5 billion.
The EBITDA is a measure of a Viatris's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$11.5 billion|
|Operating margin TTM||15.72%|
|Gross profit TTM||USD$4.6 billion|
|Return on assets TTM||3.63%|
|Return on equity TTM||0%|
|Market capitalisation||USD$8.6 billion|
TTM: trailing 12 months
How to short and sell Viatris shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "MYL.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 47.1 million Viatris shares held short by investors – that's known as Viatris's "short interest". This figure is 1.4% up from 46.5 million last month.
There are a few different ways that this level of interest in shorting Viatris shares can be evaluated.
Viatris's "short interest ratio" (SIR)
Viatris's "short interest ratio" (SIR) is the quantity of Viatris shares currently shorted divided by the average quantity of Viatris shares traded daily (recently around 4.2 million). Viatris's SIR currently stands at 11.15. In other words for every 100,000 Viatris shares traded daily on the market, roughly 11150 shares are currently held short.
However Viatris's short interest can also be evaluated against the total number of Viatris shares, or, against the total number of tradable Viatris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viatris's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Viatris shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Viatris shares, roughly 111 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Viatris.
Find out more about how you can short Viatris stock.
Viatris's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Viatris.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Viatris's total ESG risk score
Total ESG risk: 37.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Viatris's overall score of 37.23 (as at 12/31/2018) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Viatris is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Viatris's environmental score
Environmental score: 1.95/100
Viatris's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Viatris's social score
Social score: 20.21/100
Viatris's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Viatris's governance score
Governance score: 14.07/100
Viatris's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Viatris is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Viatris's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Viatris scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Viatris has a damaged public profile.
Environmental, social, and governance (ESG) summary
|Total ESG score||37.23|
|Total ESG percentile||77.8|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||4|
Viatris share dividends
We're not expecting Viatris to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have Viatris's shares ever split?
Viatris's shares were split on a 3:2 basis on 8 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Viatris shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Viatris shares which in turn could have impacted Viatris's share price.
Viatris share price volatility
Over the last 12 months, Viatris's shares have ranged in value from as little as $0.077 up to $19.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viatris's is 1.4656. This would suggest that Viatris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Frequently asked questions
More on investing
Companies are going public via direct listings and IPOs. Which should you invest in?Read more…
Biden’s plan to replace the federal fleet with American-made electric vehicles gives another boost to a red-hot sector led by Tesla.Read more…
Cruise ship stocks are sailing through murky waters, but can they rise?Read more…
More guides on Finder
How to buy Sanofi stock in Canada | $45.8
Steps to owning and managing SNY, with 24-hour and historical pricing before you buy.
How to buy NorthWestern Corporation stock in Canada
Steps to owning and managing NorthWestern Corporation stocks, with 24-hour and historical pricing before you buy.
How to buy Noble Corporation stock in Canada
Steps to owning and managing Noble Corporation stocks, with 24-hour and historical pricing before you buy.
How to buy NMI stock in Canada
Steps to owning and managing NMI stocks, with 24-hour and historical pricing before you buy.
How to buy nLIGHT stock in Canada
Steps to owning and managing nLIGHT stocks, with 24-hour and historical pricing before you buy.
How to buy NIO stock in Canada | $46.81
Steps to owning and managing NIO stocks, with 24-hour and historical pricing before you buy.
How to buy Nielsen stock in Canada
Steps to owning and managing Nielsen stocks, with 24-hour and historical pricing before you buy.
How to buy Newtek Business Services stock in Canada
Steps to owning and managing Newtek Business Services stocks, with 24-hour and historical pricing before you buy.
How to buy New Fortress Energy stock in Canada
Steps to owning and managing New Fortress Energy stocks, with 24-hour and historical pricing before you buy.
How to buy NeoGenomics stock in Canada
Steps to owning and managing NeoGenomics stocks, with 24-hour and historical pricing before you buy.